Supplemental NDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab in 1L PD-L1+ve NSCLC Accepted for Review by NMPA May 12, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA May 12, 2026
First Patient Dosed in ASPENOVA Ph 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer May 12, 2026
Positive 12-Month Follow-Up Data from Ph 2b CLOVER WaM Study Shows Durable Responses & Efficacy of Iopofosine I 131 in R/R Waldenström Macroglobulinemia May 12, 2026
FDA cleared IND for Ph 1/2 study of oral elraglusib in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers May 12, 2026
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop SC Formulations of Multiple Promising Oncology Targets May 12, 2026
First patient dosed in clinical trial of EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent GBM May 12, 2026
Evorpacept + Zanidatamab combo Generates Durable Response in Patients with Advanced HER2+ve Breast Cancer and High CD47 Expression May 12, 2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies May 12, 2026
Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer May 12, 2026
Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform May 12, 2026
CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma May 12, 2026
Kanvas Biosciences Secures $48M Series A to Deliver Novel Microbiome Therapeutics to Cancer Patients May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
Interim Results Announced of US Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% CRR, and Favorable Safety Profile May 12, 2026
Updated Interim Results Announced From LEGEND Cohort of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 12, 2026
50% ORR Announced in Recurrent Ovarian Cancer Ph 2 Trial of Ampligen, Pembrolizumab and Cisplatin May 12, 2026
Updated Positive Survival Observations from Ph 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Reported May 12, 2026
Interim Ph 2 Data for INBRX-106 in 1L HNSCC Demonstrates Potential Costimulatory Benefit Over PD-1 Monotherapy May 12, 2026
NICE issues Final Draft Guidance recommending RYBREVANT + chemo during managed access period in 1L NSCLC with EGFR ex20ins mutations in adults May 12, 2026
Protocol Amendment to NANORAY-312 Ph 3 Head and Neck Cancer Study of for JNJ-1900 (NBTXR3) Announced May 12, 2026
